Ost-müük Coherus BioSciences - CHRS CFD
Lisa lemmikuks- Kokkuvõte
- Ajaloolised andmed
- Sündmused
- Tuluaruanne
- Bilanss
- Rahavood
- Omand
Hinnavahe | 0.07 | ||||||||
Pika positsiooni ööpäeva tasu
Long position overnight fee
Mine platvormile | -0.030779% | ||||||||
Lühikese positsiooni ööpäeva tasu
Short position overnight fee
Mine platvormile | -0.013666% | ||||||||
Ööpäeva tasu aeg | 22:00 (UTC) | ||||||||
Min kauplemise kogus | 1 | ||||||||
Valuuta | USD | ||||||||
Tagatis | 20% | ||||||||
Aktsiabörs | United States of America | ||||||||
Kauplemise vahendustasu | 0% |
*Information provided by Capital.com
Eelmine sulgemine* | 7.33 |
Avatud* | 7.19 |
Aastane muutus* | -2.44% |
Päeva ulatus* | 7.09 - 7.35 |
52 nädala ulatus | 5.58-14.11 |
Keskmine maht (10 päeva) | 818.32K |
Keskmine maht (3 kuud) | 26.24M |
Turukapitalisatsioon | 696.89M |
P/E suhtarv | -100.00K |
Ringluses olevad aktsiad | 77.78M |
Tulu | 239.06M |
EPS | -3.60 |
Dividendid (% kasumist) | N/A |
Beeta | 0.88 |
Järgmine tuluaruande kuupäev | Feb 15, 2023 |
Kõigi andmete allikas on Refinitiv, välja arvatud tärniga märgitud, kus *-ga andmed on esitanud Capital.com
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
Date | Close | Sulgemishind | Change (%) | Avamishind | High | Low |
---|---|---|---|---|---|---|
Jun 29, 2022 | 7.37 | 0.30 | 4.24% | 7.07 | 7.38 | 7.07 |
Jun 28, 2022 | 7.33 | -0.24 | -3.17% | 7.57 | 7.70 | 7.21 |
Jun 27, 2022 | 7.61 | 0.13 | 1.74% | 7.48 | 7.72 | 7.34 |
Jun 24, 2022 | 7.47 | 0.03 | 0.40% | 7.44 | 7.63 | 7.19 |
Jun 23, 2022 | 7.35 | 0.71 | 10.69% | 6.64 | 7.37 | 6.63 |
Jun 22, 2022 | 6.67 | 0.40 | 6.38% | 6.27 | 6.92 | 6.27 |
Jun 21, 2022 | 6.60 | 0.30 | 4.76% | 6.30 | 6.78 | 6.30 |
Jun 17, 2022 | 6.27 | 0.35 | 5.91% | 5.92 | 6.31 | 5.89 |
Jun 16, 2022 | 5.85 | 0.11 | 1.92% | 5.74 | 5.90 | 5.58 |
Jun 15, 2022 | 5.96 | 0.06 | 1.02% | 5.90 | 6.12 | 5.81 |
Jun 14, 2022 | 5.97 | -0.12 | -1.97% | 6.09 | 6.18 | 5.87 |
Jun 13, 2022 | 6.16 | -0.32 | -4.94% | 6.48 | 6.55 | 6.09 |
Jun 10, 2022 | 6.69 | -0.48 | -6.69% | 7.17 | 7.17 | 6.69 |
Jun 9, 2022 | 7.29 | -0.30 | -3.95% | 7.59 | 7.73 | 7.27 |
Jun 8, 2022 | 7.70 | 0.25 | 3.36% | 7.45 | 7.89 | 7.45 |
Jun 7, 2022 | 7.69 | 0.39 | 5.34% | 7.30 | 7.72 | 7.30 |
Jun 6, 2022 | 7.55 | -0.03 | -0.40% | 7.58 | 7.69 | 7.28 |
Jun 3, 2022 | 7.53 | 0.20 | 2.73% | 7.33 | 7.72 | 7.33 |
Jun 2, 2022 | 7.42 | 0.18 | 2.49% | 7.24 | 7.44 | 6.98 |
Jun 1, 2022 | 7.32 | 0.13 | 1.81% | 7.19 | 7.41 | 7.06 |
Coherus BioSciences Events
Time (UTC) | Country | Event |
---|---|---|
No events scheduled |
- Aastas
- Kvartalis
2016 | 2017 | 2018 | 2019 | 2020 | 2021 | |
---|---|---|---|---|---|---|
Kogutulu | 190.106 | 1.556 | 0 | 356.071 | 475.824 | 326.551 |
Tulu | 190.106 | 1.556 | 0 | 356.071 | 475.824 | 326.551 |
Kogu tegevuskulu | 306.037 | 233.692 | 204.416 | 248.303 | 319.505 | 590.409 |
Müük/Üldine/admin kulud, kokku | 51.597 | 71.303 | 94.177 | 137.037 | 139.079 | 169.713 |
Uuringud ja arendus | 254.44 | 162.389 | 110.239 | 94.188 | 142.759 | 363.105 |
Tulud majandustegevusest | -115.931 | -232.136 | -204.416 | 107.768 | 156.319 | -263.858 |
Intressitulud (kulu), muud tulud, neto | -7.98 | -9.552 | -9.684 | -17.601 | -21.166 | -22.959 |
Muud, neto | -3.877 | 3.402 | 4.691 | 2.608 | 0.554 | -0.283 |
Netotulu enne makse | -127.788 | -238.286 | -209.409 | 92.775 | 135.707 | -287.1 |
Netotulu pärast makse | -127.788 | -238.286 | -209.409 | 89.833 | 132.244 | -287.1 |
Vähemuse intress | 0.451 | 0.116 | 0.07 | 0 | 0 | |
Netotulu enne erikulusid | -127.337 | -238.17 | -209.339 | 89.833 | 132.244 | -287.1 |
Netotulu | -127.337 | -238.17 | -209.339 | 89.833 | 132.244 | -287.1 |
Arvestatav tulu, v a erikulud | -127.337 | -238.17 | -209.339 | 89.833 | 132.244 | -287.1 |
Arvestatav tulu, koos erikuludega | -127.337 | -238.17 | -209.339 | 89.833 | 132.244 | -287.1 |
Jaotamisele kuuluv netotulu | -127.337 | -238.17 | -209.339 | 89.833 | 135.551 | -287.1 |
Keskmine jaotamisele kuuluv aktsia kohta | 41.9123 | 53.1336 | 65.0348 | 73.1859 | 83.4919 | 75.4496 |
Jaotatav EPS, v a erakorralised kulud | -3.03818 | -4.48247 | -3.21888 | 1.22746 | 1.62352 | -3.80519 |
Jaotamisele kuuluv normaal-EPS | -3.03818 | -4.47118 | -3.15891 | 1.22879 | 1.62352 | -3.80519 |
Erakorralised kulud kokku | 0 | |||||
Kulud, Kokku | 17.078 | 37.667 | 57.591 | |||
Brutokasum | 338.993 | 438.157 | 268.96 | |||
Jaotuse korrigeerimine | 3.307 |
Q1 2021 | Q2 2021 | Q3 2021 | Q4 2021 | Q1 2022 | |
---|---|---|---|---|---|
Kogutulu | 83.034 | 87.643 | 82.503 | 73.371 | 60.115 |
Tulu | 83.034 | 87.643 | 82.503 | 73.371 | 60.115 |
Kulud, Kokku | 7.511 | 16.696 | 21.28 | 12.104 | 9.37 |
Brutokasum | 75.523 | 70.947 | 61.223 | 61.267 | 50.745 |
Kogu tegevuskulu | 250.394 | 111.807 | 115.29 | 112.918 | 147.262 |
Müük/Üldine/admin kulud, kokku | 39.391 | 40.345 | 39.925 | 50.052 | 48.753 |
Uuringud ja arendus | 203.492 | 54.766 | 54.085 | 50.762 | 82.917 |
Tulud majandustegevusest | -167.36 | -24.164 | -32.787 | -39.547 | -87.147 |
Intressitulud (kulu), muud tulud, neto | -5.648 | -5.747 | -5.771 | -5.793 | -8.969 |
Muud, neto | 0.061 | 0.011 | 0.03 | -0.385 | 0.032 |
Netotulu enne makse | -172.947 | -29.9 | -38.528 | -45.725 | -96.084 |
Netotulu pärast makse | -172.947 | -29.9 | -38.528 | -45.725 | -96.084 |
Netotulu enne erikulusid | -172.947 | -29.9 | -38.528 | -45.725 | -96.084 |
Netotulu | -172.947 | -29.9 | -38.528 | -45.725 | -96.084 |
Arvestatav tulu, v a erikulud | -172.947 | -29.9 | -38.528 | -45.725 | -96.084 |
Arvestatav tulu, koos erikuludega | -172.947 | -29.9 | -38.528 | -45.725 | -96.084 |
Jaotamisele kuuluv netotulu | -172.947 | -29.9 | -38.528 | -45.725 | -96.084 |
Keskmine jaotamisele kuuluv aktsia kohta | 72.8329 | 75.5597 | 79.0132 | 76.8441 | 77.2537 |
Jaotatav EPS, v a erakorralised kulud | -2.37457 | -0.39571 | -0.48761 | -0.59504 | -1.24375 |
Dividends per Share - Common Stock Primary Issue | 0 | 0 | 0 | 0 | |
Jaotamisele kuuluv normaal-EPS | -2.37457 | -0.39571 | -0.48761 | -0.59504 | -1.16321 |
Ootamatud kulutused (tulu) | 6.222 |
- Aastas
- Kvartalis
2016 | 2017 | 2018 | 2019 | 2020 | 2021 | |
---|---|---|---|---|---|---|
Käibevarad kokku | 161.486 | 145.477 | 84.433 | 343.009 | 767.479 | 602.323 |
Raha ja lühiajalised investeeringud | 124.947 | 126.911 | 72.356 | 177.668 | 541.158 | 417.195 |
Raha ja ekvivalendid | 124.947 | 126.911 | 72.356 | 177.668 | 541.158 | 417.195 |
Laekumata arved, neto | 1.859 | 0 | 141.992 | 157.046 | 123.022 | |
Prepaid Expenses | 31.634 | 18.364 | 10.285 | 13.542 | 25.042 | 24.464 |
Other Current Assets, Total | 3.046 | 0.202 | 0.133 | 0 | ||
Total Assets | 178.485 | 162.611 | 99.467 | 408.927 | 841.649 | 679.334 |
Property/Plant/Equipment, Total - Net | 10.772 | 12.773 | 6.66 | 16.489 | 20.064 | 16.006 |
Property/Plant/Equipment, Total - Gross | 16.798 | 22.575 | 19.697 | 32.785 | 36.114 | 32.855 |
Accumulated Depreciation, Total | -6.026 | -9.802 | -13.037 | -16.296 | -16.05 | -16.849 |
Goodwill, Net | 0.943 | 0.943 | 0.943 | 0.943 | 0.943 | 0.943 |
Intangibles, Net | 2.62 | 2.62 | 2.62 | 2.62 | 2.62 | 2.62 |
Other Long Term Assets, Total | 2.664 | 0.798 | 4.811 | 45.866 | 50.543 | 57.442 |
Total Current Liabilities | 56.376 | 28.395 | 33.261 | 114.969 | 145.653 | 165.327 |
Accounts Payable | 19.706 | 15.481 | 15.294 | 25.985 | 15.201 | 16.159 |
Accrued Expenses | 24.48 | 8.54 | 17.548 | 88.984 | 129.164 | 148.427 |
Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities, Total | 12.19 | 4.374 | 0.419 | 0.728 | ||
Total Liabilities | 157.958 | 130.787 | 138.058 | 303.713 | 560.675 | 581.608 |
Total Long Term Debt | 100.256 | 101.608 | 103.092 | 178.386 | 404.898 | 408.778 |
Long Term Debt | 100.256 | 101.608 | 103.092 | 178.386 | 404.023 | 408.28 |
Minority Interest | -1.173 | -1.289 | 0 | |||
Other Liabilities, Total | 2.499 | 2.073 | 1.705 | 10.358 | 10.124 | 7.503 |
Total Equity | 20.527 | 31.824 | -38.591 | 105.214 | 280.974 | 97.726 |
Common Stock | 0.005 | 0.006 | 0.007 | 0.007 | 0.007 | 0.007 |
Additional Paid-In Capital | 558.474 | 808.06 | 946.515 | 1000.76 | 1043.99 | 1147.84 |
Retained Earnings (Accumulated Deficit) | -537.322 | -775.492 | -984.831 | -894.998 | -762.754 | -1049.85 |
Other Equity, Total | -0.63 | -0.75 | -0.282 | -0.558 | -0.27 | -0.27 |
Total Liabilities & Shareholders’ Equity | 178.485 | 162.611 | 99.467 | 408.927 | 841.649 | 679.334 |
Total Common Shares Outstanding | 45.8082 | 59.8405 | 68.3027 | 70.3667 | 72.5134 | 76.9301 |
Total Inventory | 1.659 | 9.807 | 44.233 | 37.642 | ||
Accounts Receivable - Trade, Net | 141.992 | 157.046 | 123.022 | |||
Current Port. of LT Debt/Capital Leases | 0.56 | 0.741 | ||||
Capital Lease Obligations | 0.875 | 0.498 |
Mar 2021 | Jun 2021 | Sep 2021 | Dec 2021 | Mar 2022 | |
---|---|---|---|---|---|
Käibevarad kokku | 617.261 | 660.013 | 673.039 | 602.323 | 512.443 |
Raha ja lühiajalised investeeringud | 399.503 | 454.421 | 468.707 | 417.195 | 325.68 |
Raha ja ekvivalendid | 259.489 | 329.738 | 360.54 | 417.195 | 325.68 |
Lühiajalised investeeringud | 140.014 | 124.683 | 108.167 | ||
Laekumata arved, neto | 140.41 | 141.825 | 136.346 | 123.022 | 117.039 |
Accounts Receivable - Trade, Net | 140.41 | 141.825 | 136.346 | 123.022 | 117.039 |
Total Inventory | 51.613 | 39.668 | 37.583 | 37.642 | 36.945 |
Prepaid Expenses | 25.735 | 24.099 | 30.403 | 24.464 | 32.779 |
Total Assets | 693.303 | 739.542 | 741.726 | 679.334 | 593.387 |
Property/Plant/Equipment, Total - Net | 19.1 | 18.03 | 8.505 | 16.006 | 7.998 |
Property/Plant/Equipment, Total - Gross | 36.379 | 36.181 | 27.547 | 32.855 | 25.614 |
Accumulated Depreciation, Total | -17.279 | -18.151 | -19.042 | -16.849 | -17.616 |
Goodwill, Net | 0.943 | 0.943 | 0.943 | 0.943 | |
Intangibles, Net | 2.62 | 2.62 | 2.62 | 2.62 | 3.563 |
Other Long Term Assets, Total | 53.379 | 57.936 | 56.619 | 57.442 | 69.383 |
Total Current Liabilities | 257.601 | 287.052 | 320.348 | 165.327 | 153.748 |
Accounts Payable | 15.482 | 14.568 | 45.707 | 16.159 | 21.092 |
Accrued Expenses | 134.495 | 153.473 | 149.363 | 148.427 | 132.656 |
Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | 0 |
Current Port. of LT Debt/Capital Leases | 107.624 | 119.011 | 125.278 | 0.741 | |
Total Liabilities | 565.632 | 583.322 | 610.966 | 581.608 | 580.824 |
Total Long Term Debt | 298.906 | 287.075 | 281.895 | 408.778 | 420.456 |
Long Term Debt | 298.037 | 287.075 | 281.895 | 408.28 | 420.456 |
Capital Lease Obligations | 0.869 | 0.498 | |||
Other Liabilities, Total | 9.125 | 9.195 | 8.723 | 7.503 | 6.62 |
Total Equity | 127.671 | 156.22 | 130.76 | 97.726 | 12.563 |
Common Stock | 0.007 | 0.007 | 0.007 | 0.007 | 0.007 |
Additional Paid-In Capital | 1063.67 | 1122.08 | 1135.16 | 1147.84 | 1158.77 |
Retained Earnings (Accumulated Deficit) | -935.701 | -965.601 | -1004.13 | -1049.85 | -1145.94 |
Other Equity, Total | -0.307 | -0.267 | -0.273 | -0.27 | -0.272 |
Total Liabilities & Shareholders’ Equity | 693.303 | 739.542 | 741.726 | 679.334 | 593.387 |
Total Common Shares Outstanding | 73.1229 | 76.4647 | 76.5833 | 76.9301 | 77.3382 |
- Aastas
- Kvartalis
2016 | 2017 | 2018 | 2019 | 2020 | 2021 | |
---|---|---|---|---|---|---|
Netotulu/algväärtus | -127.788 | -238.286 | -209.409 | 89.833 | 132.244 | -287.1 |
Raha majandustegevusest | -252.545 | -200.286 | -159.266 | 28.355 | 154.145 | -37.432 |
Raha majandustegevusest | 2.996 | 3.398 | 3.235 | 3.259 | 2.888 | 3.454 |
Mittelikviidsed varad | 31.461 | 39.735 | 36.611 | 49.191 | 51.067 | 203.266 |
Makstud intressid | 6.939 | 8.2 | 8.2 | 15.263 | 16.959 | 18.684 |
Muutused tööjõus | -159.214 | -5.133 | 10.297 | -113.928 | -32.054 | 42.948 |
Tulu investeeringutelt | -6.515 | -4.417 | -1.188 | -12.732 | -14.401 | -138.41 |
Kapitalikulutused | -6.515 | -4.573 | -0.789 | -1.822 | -7.231 | -1.289 |
Muud rahavood investeeringutelt, kokku | 0 | 0.156 | -0.399 | -10.91 | -7.17 | -137.121 |
Rahavood investeeringutelt | 226.179 | 206.787 | 105.421 | 89.37 | 223.946 | 51.879 |
Rahavoogudesse investeerimine | -0.705 | -0.544 | -0.815 | -0.88 | -1.753 | |
Aktsiate emiteerimine (tagasiost), neto | 127.623 | 207.331 | 105.421 | 17.23 | 21.229 | 54.304 |
Laenu väljastamine (kustutamine), neto | 99.261 | 0 | 72.955 | 203.597 | -0.672 | |
Muutused valuutakursside kõikumisest | -0.398 | -0.12 | 0.468 | -0.276 | ||
Rahaline kogumuutus | -33.279 | 1.964 | -54.565 | 104.717 | 363.69 | -123.963 |
Cash Taxes Paid | 1.732 | 3.953 | 1.221 |
Mar 2021 | Jun 2021 | Sep 2021 | Dec 2021 | Mar 2022 | |
---|---|---|---|---|---|
Net income/Starting Line | -172.947 | -202.847 | -241.375 | -287.1 | -96.084 |
Cash From Operating Activities | 1.367 | 1.179 | 14.89 | -37.432 | -54.045 |
Cash From Operating Activities | 0.849 | 1.726 | 2.618 | 3.454 | 0.767 |
Non-Cash Items | 166.9 | 171.468 | 190.497 | 203.266 | 58.389 |
Changes in Working Capital | 6.565 | 30.832 | 63.15 | 42.948 | -17.117 |
Cash From Investing Activities | -285.475 | -261.89 | -245.9 | -138.41 | -35.615 |
Capital Expenditures | -0.145 | -0.56 | -0.821 | -1.289 | -0.615 |
Other Investing Cash Flow Items, Total | -285.33 | -261.33 | -245.079 | -137.121 | -35 |
Cash From Financing Activities | 2.439 | 49.291 | 50.392 | 51.879 | -1.855 |
Financing Cash Flow Items | -1.89 | -2.043 | -2.222 | -1.753 | -2.839 |
Issuance (Retirement) of Stock, Net | 4.329 | 51.334 | 52.614 | 54.304 | 0.544 |
Net Change in Cash | -281.669 | -211.42 | -180.618 | -123.963 | -91.515 |
Issuance (Retirement) of Debt, Net | 0 | 0 | -0.672 | 0.44 |
Investori nimi | Investori liik | Ringluse protsent | Hoitud osakud | Muutus osakutes | Hoidmise kuupäev | Hinnang käibele |
---|---|---|---|---|---|---|
BlackRock Institutional Trust Company, N.A. | Investment Advisor | 14.3792 | 11183875 | 88569 | 2022-09-30 | LOW |
Temasek Holdings Pte. Ltd. | Sovereign Wealth Fund | 9.49 | 7381116 | 0 | 2022-09-30 | LOW |
AllianceBernstein L.P. | Investment Advisor/Hedge Fund | 7.8517 | 6106861 | 431412 | 2022-09-30 | LOW |
The Vanguard Group, Inc. | Investment Advisor/Hedge Fund | 6.7052 | 5215182 | 350839 | 2022-09-30 | LOW |
State Street Global Advisors (US) | Investment Advisor/Hedge Fund | 6.5645 | 5105771 | -1277332 | 2022-09-30 | LOW |
JP Morgan Asset Management | Investment Advisor | 5.5835 | 4342765 | -188757 | 2022-09-30 | LOW |
Kohlberg Kravis Roberts & Co. L.P. | Private Equity | 3.9035 | 3036076 | 0 | 2022-09-30 | LOW |
Aristotle Capital Boston, LLC | Investment Advisor | 2.7532 | 2141380 | -180788 | 2022-09-30 | LOW |
Medical Strategy GmbH | Investment Advisor | 2.3391 | 1819281 | 85000 | 2022-09-30 | LOW |
Perceptive Advisors LLC | Private Equity | 2.1434 | 1667123 | -1978348 | 2022-09-30 | LOW |
Columbia Threadneedle Investments (US) | Investment Advisor/Hedge Fund | 2.032 | 1580477 | -175396 | 2022-09-30 | LOW |
JPMorgan Asset Management U.K. Limited | Investment Advisor/Hedge Fund | 1.9029 | 1479999 | -17637 | 2022-09-30 | LOW |
Geode Capital Management, L.L.C. | Investment Advisor/Hedge Fund | 1.5804 | 1229209 | 32357 | 2022-09-30 | LOW |
Lanfear (Dennis M) | Individual Investor | 1.5152 | 1178502 | 75345 | 2023-01-20 | LOW |
Disciplined Growth Investors, Inc. | Investment Advisor | 1.4555 | 1132096 | 886075 | 2022-09-30 | LOW |
Peregrine Capital Management, LLC | Investment Advisor | 1.4368 | 1117482 | -12124 | 2022-12-31 | LOW |
BlackRock Financial Management, Inc. | Investment Advisor/Hedge Fund | 1.3587 | 1056740 | 18831 | 2022-09-30 | LOW |
C WorldWide Asset Management Fondsmaeglerselskab A/S | Investment Advisor | 1.1937 | 928464 | 0 | 2022-09-30 | LOW |
Citi Investment Research (US) | Research Firm | 1.0771 | 837715 | 68015 | 2022-09-30 | LOW |
Balyasny Asset Management LP | Hedge Fund | 1.0285 | 799950 | -278159 | 2022-09-30 | HIGH |
Miks valida Capital.com? Meie numbrid räägivad iseenda eest.
Capital.com GroupKauplejad
Igakuiste aktiivsete klientide arv
Igakuine investeerimise maht
Igakuiselt välja võetud
Kauplemiskalkulaator
Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).
- 1:1
- 2:1
- 5:1
- 10:1
- 20:1
- 20
- 100
- 500
- 1000
- 10000
Coherus BioSciences Company profile
Ettevõttest Coherus BioSciences
Coherus BioSciences, Inc. on kommertsjärgus biofarmatseutiline ettevõte. Ettevõte keskendub vähktõve raviks kasutatavate immunoteraapiate uurimisele, arendamisele ja turustamisele. See tegutseb inimtervishoius kasutatavate farmaatsiatoodete segmendi arendamise ja turustamisega. Ettevõtte tooteprogrammis on kolm tootekandidaati: toripalimab, PD-1-vastane antikeha, mida arendatakse koostöös Junshi Biosciences Co., Ltd.'ga, CIMERLI, Lucentise biosimilar-kandidaat, millele Bioeq on müügilitsentsi andnud Ameerika Ühendriikides ja Kanadas, ning bevatsizumabi (Avastin) biosimilar, millele Innovent Biologics (Suzhou) Co., Ltd. on müügilitsentsi andnud Ameerika Ühendriikides. Ettevõte arendab ka sisemist immunonkoloogilist tooteprogrammi prekliinilises ja translatiivses teaduses, bioinformaatikas, analüütilises iseloomustuses, protsessiteaduslikus tehnikas ning kliinilis-regulatiivses arendustegevuses ja turustamises.
Industry: | Bio Therapeutic Drugs |
C/O Dennis M. Lanfear
201 Redwood Shores Parkway, Suite 200
REDWOOD CITY
CALIFORNIA 94065
US
Tuluaruanne
- Annual
- Quarterly
Teised on vaadanud veel
Kas otsite jätkuvalt vahendajat, keda saab usaldada?
Ühinege 485,000+ kauplejaga üle kogu maailma, kes valisid kauplemiseks veebisaidi Capital.com